BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.
Ekstern lenke til BerGenBio ASA
Jonas Lies vei 91
Bergen, Norway, NO
1 Robert Robinson Ave
Oxford, Oxfordshire OX44GA, GB
BioTuesdays writes about BerGenBio ASA and our pioneering work to develop #AXL targeted therapies👇 #AXL #bemcentinib #NSCLC
🌟 Feature Article 🌟 Discover how BerGenBio ASA (OSE:BGBIO) aims to combat aggressive diseases with pioneering AXL therapies. In our latest #BioTuesdays feature, CEO Martin Olin shares insights into their groundbreaking work and the potential of their lead compound, bemcentinib. 🔗 https://lnkd.in/gmkJbFx9 Kilmer Lucas Inc.
Today, BerGenBio released the Q1 2024 report. CEO Martin Olin comments: #bemcentinib #cancerresearch #lungcancer
Today, we announced a National Cancer Institute funded Ph1b/2 clinical collaboration with UT Health San Antonio and Sobi - Swedish Orphan Biovitrum AB (publ)® based on UT Health San Antonio’s ground breaking research published in Cell Reports in September 2023 and Cancer Research in April 2020. We will collaborate to study BerGenBio’s selective #AXL inhibitor, #bemcentinib, in combination with Sobi - Swedish Orphan Biovitrum AB (publ)’s JAK2 inhibitor, pacritinib, in patients with advanced lung adenocarcinoma. The Ph1b/2 study will be led by Dr. Josephine Taverna, MD, at the Mays Cancer Center and Assistant Professor in the Division of Hematology and Oncology at UT Health San Antonio and is based on Dr. Taverna and colleagues’ research demonstrating that #AXL and JAK-STAT3 work together to transmit signals that promote tumor growth and metastasis in advanced #lungcancer. #bemcentinib #AXL #lungcancer
Today, our CEO Martin Olin visited the TV studio of Finansavisen, one of Norway’s leading business media outlets. The interview led by TV host Marius Lorentzen gave a review of the company's activities and our progress with the study of our lead compound #bemcentinib. Watch the interview (in Norwegian) here: https://lnkd.in/gRKPRYjh #NSCLC #STK11 #Bemcentinib #Biotech #Oncology
Following a positive recommendation from the independent Data and Safety Monitoring Board (DSMB), BerGenBio today announced the initiation of the Phase 2a portion of the main clinical trial (BGBC016). #Bemcentinib #NSCLC #STK11 #Cancerresearch #AXL
The Radium podcast is a leading oncology podcast in Norway, hosted by RADFORSK Investeringsstiftelse's CEO Jonas Einarsson and Elisabeth Andersen, Kirkeng. In the latest episode published today, our CEO Martin Olin talks about BerGenBio's technology, how the clinical study BGBC016 (1L NSCLC STK11m) continues to progress as expected, the company's financial position and much more. 🎧 Tune in (in Norwegian only): https://lnkd.in/gdBMss35 #NSCLC #Oncology #Biotech #Cancer #STK11 #AXL #Bemcentinib #AXL #
This week, CEO Martin Olin presented BerGenBio’s work to meet #NSCLC patients’ high unmet medical need at the Carnegie Investment Bank's Nordic Healthcare Seminar in Stockholm. You can access the presentation here: https://lnkd.in/dMsf_CYy #Carnegie #Bemcentinib #Oncology #NSCLC #STK11
Get to know BerGenBio’s CEO Martin Olin ⬇️ He started off his career in the finance sector, but shortly after joined Novo Nordisk back in the 1990s. Inspired by his grandmother he decided to dedicate the rest of his career to the healthcare industry. In today’s profile interview with Finansavisen he talks about how our lead compound bemcentinib represents a novel therapeutic option for lung cancer patients, the encouraging clinical results we have received so far and the company’s long-term ambitions. «Lung cancer is a devastating disease with a low survival rate. We have shown that we can fight back with our method. If we get the results we hope for, the commercial opportunities are enormous», Olin says. Read the full interview here (in Norwegian and behind paywall): https://lnkd.in/dFdP7R24 #NSCLC #Cancer #Oncology #STK11 #bemcentinib #AXL #CEO #Finansavisen
BerGenBio ASA's lead compound #bemcentinib targets #NSCLC patients with mutations in the #STK11 gene. In this video by Lung Cancer Foundation of America , Dr. Salman Punekar at New York University explains the importance of identifying #STK11 mutations in lung cancer, limitations of current therapies, and the patient benefits of clinical trial participation. Link full episode: https://lnkd.in/dvr_etwQ
Today, BerGenBio reported Q4 2023 results. CEO Martin Olin comments:
Siste runde
Gjeld etter børsnotering$23,128,637.00